Analysis finds ties between pharmaceutical industry and federal government are deepening; Mississippi readies a Medicaid work requirement waiver; research identifies danger of interactions between herbal supplements and prescription medications.
An analysis from Kaiser Health News found that the ties between the pharmaceutical industry and the federal government are deepening. Alex Azar, the newly confirmed HHS secretary, is just the latest example of the so-called “revolving door” connecting the federal government and the drug industry. There are more than 300 former congressional staffers who work for pharma companies or a pharma lobbying firm and nearly a dozen former employees of the drug industry now work for the government.
Although Medicaid beneficiaries in Kentucky just sued the government over new work requirements to receive benefits, Mississippi is preparing its own waiver request to implement the same restriction. According to The Hill, the state is seeking a 5-year waiver to require able-bodied adults to participate in at least 20 hours of workforce training every week. If beneficiaries aren’t participating in approved activities, such as working, volunteering, or enrolled in a drug treatment program, they will be kicked off Medicaid. Mississippi’s waiver request differs from Kentucky, which had expanded Medicaid and targeted its requirements at those newly eligible beneficiaries.
New research has found that mixing common herbal supplements with prescription medications can result in dangerous interactions. TIME reported that the challenge is that people often don’t tell their healthcare providers what over-the-counter drugs and supplements they take. Herbals supplements can result in medications being less effective. The research found that of 49 cases of adverse drug reactions reviewed, herb—drug interactions were probable for 51%.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More